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ABSTRACT 
The present study was conducted to evaluate the antihypertensive effect 
of an Ayurvedic formulation Trinpanchmool Kwath in the management of 
essential hypertension. The study was conducted in 30 patients selected 
from OPD and IPD of R.G.G. P.G.A.C. and Hospital, Paprola. Patients were 
randomly divided into three groups. Group-I patients were managed with 
Trinpanchmool Kwath, Group-II patients were managed with Tab 
Chlorthalidone and Group-III patients were managed with both 
Trinpanchmool Kwath and Tab. Chlorthalidone. The results obtained were 
analysed on the basis of various objective and subjective parameters. 
However change in blood pressure was the main criteria for assessing the 
effect of the therapy. Statistically highly significant reduction was 
observed in systolic and diastolic blood pressure after 45 days of therapy. 
In Group-I systolic blood pressure reduced by 9.374%, in Group-II systolic 
blood pressure decreased by 15.46% and in Group-III systolic blood 
pressure decreased by 16.86%. Similarly in Group-I diastolic blood 
pressure decreased by 8.195%, in Group-II showed 11.250% reduction 
and in Group-III diastolic blood pressure decreased by 12.17% after 
completion of therapy. Results revealed that therapy given in Group-III i.e. 
the combination of Trinpanchmool Kwath and Tab. Chlorthalidone showed 
best results as compared to other groups. Group-II, in which patients were 
managed with Tab Chlorthalidone showed better results over Group-I 
where only Trinpanchmool Kwath was given to the patients. However 
statistically highly significant reduction in both systolic and diastolic 
pressure was observed in all three groups.  
 
INTRODUCTION
The WHO has located India as one of the 
countries that are going to report most of the 
lifestyle disorders in the near future. The major 
lifestyle diseases identified in India include Heart 
disease, Hypertension, Obesity, Diabetes mellitus, 
and Cancer. Hypertension is multifactorial disorder. 
Increased stress level, less physical activity, obesity 
and overuse of salt are among its common 
aetiological factors. It is known as a worldwide 
problem as 15-20% of all adults are affected by this 
condition[1]. Hypertension doubles the risk of 
coronary heart disease, cardiac hypertrophy with 
heart failure, aortic distension and renal failure, 
neurogenic effect and development of cerebro- and 
cardiovascular disorders[2]. It is also known as a 
high risk factor for brain ischemia, stroke, 
arteriosclerosis, end stage renal disease and 
myocardial infarction[3]. It is expected to cause 
more than half of the estimated 17 million deaths 
per year resulting from cardiovascular disease 
worldwide. Highly populated developing Asian 
countries, such as India and China, have a large 
absolute number of individuals with hypertension. 
Globally, an estimated 26% of the world’s 
population has hypertension, and the prevalence is 
expected to increase to 29% by 2025[4]. 
 The conventional antihypertensive drugs have 
many adverse effects and are not well tolerated 
Research Article 
*Address for correspondence 
Dr. Prerna 
Research Scholar,  
P.G. Dept of Kayachitiksa, 
RGGPG Ayurvedic College, 
Paprola, Himachal Pradesh, 
India. 
Email: 
doctorprerna198@gmail.com  
AYUSHDHARA, 2020;7(Suppl 1):1-10 
 AYUSHDHARA | September - October 2020 | Vol 7 | Suppl 1  2 
which leads to noncompliance, switching, and 
discontinuation of treatment. So it is a need of the 
time to get a safe and cost-effective remedy for 
hypertension. 
AIMS AND OBJECTIVES 
Primary Objectives 
To clinically evaluate the efficacy of 
Trinpanchmool Kwath in the management of 
essential hypertension. 
Secondary Objectives 
To assess the safety of Trinpanchmool 
Kwath in the patients of essential hypertension. 
MATERIALS AND METHOD 
Selection of Patient 
 Total 30 study subjects were selected from 
OPD/IPD of R.G.G.P.G. Ayurvedic College and 
Hospital, Paprola, Dist. Kangra (H.P.), irrespective of 
caste, gender, race and religion. A detailed history 
was obtained, physical examination was conducted 
and relevant investigations of study subjects were 
carried out before the enrolment and after the 
completion of trial period. 
Protocol of Research 
1. I.E.C Approval: The detailed synopsis of the 
study was submitted to I.E.C. and after getting 
clearance from committee this study has been 
undertaken. IEC clearance was obtained vide 
letter No. Ayu/IEC/2017/1138 Dated 
1/10/2018. 
2. Consent: Written and informed consent of 
patients was taken before inclusion in the trial. 
3. CTRI registration: The study has also been 
registered in clinical trial registry of India vide 
CTRI No. CTRI/2019/11/022015 dated 
15/11/2019. 
History Performa 
A special case history proforma was 
prepared. All the sign/symptoms, blood pressure 
reading were depicted in this proforma along with 
pulse pressure, before inclusion and after 
completion of study. 
Criteria of Diagnosis 
Diagnosis was mainly based on readings of 
sphygmomanometer. With the help of 
sphygmomanometer, 3 consecutive reading of 
blood pressure in 3 different positions (sitting, 
standing and supine) on both arms were taken. 
Their mean value was calculated for each arm 
separately and the highest reading was utilized for 
diagnosing and categorizing the patients according 
to 7th Joint National Committee on Detection, 
Education and Treatment of High Blood Pressure. 
Only newly diagnosed patients of stage– I 
hypertension were included in trial according to 
JNC7 guideline. To determine systolic and diastolic 
blood pressure the Kortokoff sound 1 and 5 were 
used. 
Inclusion criteria 
a) Patients willing for trial. 
b) Patients in age group between 20–70 years. 
c) Patients suffering from stage-I hypertension (i.e. 
Systolic Blood Pressure 140–159mm of Hg and 
Diastolic Blood Pressure 90–99mm of Hg 
according to JNC7). 
d) Patients suffering from isolated systolic 
hypertension (i.e. Systolic Blood Pressure 140-
159mm of Hg and Diastolic Blood Pressure 
<90mm of Hg). 
Exclusion criteria 
a) Patients not willing for the trial. 
b) Patients < 20 years and >70 years of age. 
c) Stage II hypertension i.e. Systolic ≥ 160mmHg 
and Diastolic ≥ 100mmHg. 
d) Patients suffering from secondary hypertension. 
e) Any other condition which the principal 
investigator thought may jeopardize the study. 
f) Patients who had participated in any clinical 
study/trial in past 6 months. 
Investigations 
Hb%, TLC, DLC, ESR, FBS, Blood Urea, 
Serum Creatinine, SGOT, SGPT, S. Lipid profile (S. 
Cholesterol, S.Triglycerides, HDL, LDL, VLDL), 
Urine- Routine and Microscopic examination 
Method of Study  
Total 30 patients of Hypertension were 
selected for the present clinical study; they were 
randomly divided and managed into the following 
groups: 
Trial Group I- Total 10 patients were registered in 
this group out of them, 9 patients completed the 
trial. In this group hypertensive patients were 
managed with Trinpanchmool Kwath. 
Trial Drug 
Interventional products were prepared at 
Government Charaka Ayurvedic Pharmacy, Paprola 
vide Licence No.HP-Ay-87. 
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Table 1: Ingredients of Trinpanchmool Kwath 
S. No Name Latin name Family Part used Proportion 
1. Kush Desmostachya Bipinnata Poaceae Root 1 part 
2. Kash Saccharum Spontaneum Poaceae Root 1 part 
3. Shara Saccharum Munja Poaceae Root 1 part 
4. Ikshu Saccharum officinarum Poaceae Root 1 part 
5. Darbh Imperata cylindrical Poaceae Root 1 part 
Dosage: Trinpanchmool Kwath was given in the 
dose of 50ml BD. 
Trial Group II: Total 10 patients were registered in 
this group out of them, 9 patients completed the 
trial. In this group patient were managed with Tab. 
Chlorthalidone in the dose12.5mg once a day. 
Trial Group III: Total 10 patients were registered 
in this group, all of them completed the trial. In this 
group patients were managed with both 
Trinpanchmool Kwath 50ml BD and Chlorthalidone 
12.5mg OD. 
Duration of Trial- 45 days  
Follow up and Assessment of the Study Subjects: 
A thorough assessment of the study subjects 
was done before commencement of the therapy 
(day zero) and at the 15th, 30th and 45th day i.e. at 
the time of the completion of therapy. The effects of 
treatment were assessed on the basis of various 
subjective and objective parameters. However the 
change in systolic, diastolic and mean blood 
pressure was the main criteria. Laboratory 
investigations were carried out before 
commencement and after completion of the 
treatment. 
A) Objective Criteria 
 Systolic and Diastolic Blood Pressure 
 Pulse Pressure 
 Mean Arterial Pressure 
B) Subjective Criteria 
Subjective parameters were graded from 0 to 3 
according to severity. 
Shiroruja 
Shiroruja (Headache) Score 
No Headache 0 
Mild headache but patient was able to 
do casual work 
1 
Continuous headache which hampers 
routine work 
2 
Patient unable to do routine work 3 
 
 
Bhrama (Giddiness) 
Bhrama (Giddiness) Score 
Giddiness 0 
Occasional but patient able to do 
usual work 
1 
Continuous giddiness which 
hampers routine work 
2 
Patient unable to do any work 3 
Hridadrava (Palpitation) 
Hridadrava Score 
No palpitation 0 
Occasional palpitation 1 
Palpitation hampers routine work  2 
Continuous palpitation 3 
Swasa Kricchrita (Breathlessness) 
Swasa Kricchrita Score 
No dyspnoea on exertion  0 
Mild dyspnoea and able to do routine 
work 
1 
Moderate dyspnoea which hampers 
routine work  
2 
Dyspnoea at rest making patient 
unable to do routine work 
3 
Statistical Assessment 
 Data generated during study was collected 
and analyzed statistically. The improvement in the 
status of patient was assessed on the grades of 
various variables compared between pre trial and 
post trial values in terms of percentage (based on 
mathematical mean and its difference) and also 
paired ‘t’ test and Anova test was applied wherever 
it was felt necessary. The result were interpreted at 
the level of p<0.001as highly significant, p<0.05 as 
significant and p>0.05 as insignificant. 
OBSEVATIONS AND RESULTS 
Out of 30 registered study subjects 
maximum were married (96.67%) female (56.67%) 
of age group between 55-70 yrs (46.67%) dwelling 
in rural area (98.33%) and Hindu (100%) by 
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religion.46.67% were educated up to metric and 
majority of them were involved in house work 
(33%), taking mixed diet 76.67%) and having 
normal sleep (66.67%). 23.33% of study subjects 
had no addiction but rest of them were addicted 
either to smoking or alcohol. Majority of individuals 
had Vata-Pittaj Deha Prakriti (63.33%) and Rajsik 
Manas Prakriti (73.33%). Majority were Mamsa 
Sara (43.33%) with Madhyam Samhanana (100%), 
Satva (83.33%), Satmaya (60%), Pramana (90%) 
and Madhyama Aahara Shakti (70%) and Vyayama 
Shakti (50). 
Table 2: Effect of Therapy on Objective Criteria 
Objective Criteria Group  Mean Score  Percent Change  
BT AT 
Systolic Blood Pressure (in mm of Hg) Group-I 148.60 134.67 9.37% 
Group-II 150.10 126.89 15.46% 
Group-III 153.00 127.20 16.86% 
Diastolic Blood Pressure (in mm of Hg) Group-I 89.80 82.44 8.19% 
Group-II 92.40 82.00 11.25% 
Group-III 92.00 80.80 12.17% 
Mean Arterial  
Pressure (in mm of Hg) 
Group-I 109.70 99.73 9.08% 
Group-II 112.01 96.93 13.46% 
Group-III 112.29 96.24 14.28% 
Pulse Pressure (in mm of Hg) Group-I 59.8 52.0 13.04% 
Group-II 58.9 44.8 23.70% 
Group-III 61.0 46.4 23.93% 
Pulse Rate (per minute) Group-I 76.40 74.00 3.14% 
Group-II 73.20 73.11 0.12% 
Group-III 76.80 73.00 4.94% 
 
Objective  
Criteria 
Group Mean 
Diff.  
SD+ SE+  ‘t’  
value  
‘p’  
value  
Intergroup  
p-value 
Systolic Blood 
Pressure (in mm of 
Hg) 
Group-I 13.11 6.009 2.003 6.545 <0.001 0.002 
Group-II 22.56 9.710 3.237 6.969 <0.001 
Group-III 25.80 4.050 1.281 20.146 <0.001 
Diastolic Blood 
Pressure (in mm of 
Hg) 
Group-I 7.33 4.472 1.491 4.919 <0.001 0.187 
Group-II 10.22 5.696 1.899 5.384 <0.001 
Group-III 11.20 3.425 1.083 10.340 <0.001 
Mean Arterial  
Pressure (in mm of 
Hg) 
Group-I 9.71 5.192 1.731 5.611 <0.001 0.013 
Group-II 14.78 5.545 1.848 8.002 <0.001 
Group-III 16.04 2.170 0.686 23.386 <0.001 
Pulse Pressure (in 
mm of Hg) 
Group-I 7.11 5.487 1.829 3.888 0.005 0.071 
Group-II 13.67 11.790 3.930 3.478 0.008 
Group-III 14.60 6.186 1.956 7.464 <0.001 
Pulse Rate (per 
minute) 
Group-I 2.44 6.839 2.280 1.072 0.315 0.672 
Group-II 0.67 7.180 2.603 0.256 0.804 
Group-III 3.80 8.025 2.538 1.497 0.169 
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Table 3: Effects of therapy on Subjective Criteria 
Criteria Group  Mean Score  Percent Change  
BT AT 
Headache 
(Shiroruja) 
 
Group-I 1.6 1.1 30.64% 
Group-II 1.4 0.7 44.24% 
Group-III 1.9 0.9 52.63% 
Giddiness 
(Bhrama) 
Group-I 1.1 0.6 40% 
Group-II 1.2 0.6 53% 
Group-III 1.7 0.7 58% 
Palpitation 
(Hriddravata) 
Group-I 0.5 0.2 55.6% 
Group-II 0.7 0.2 68.2% 
Group-III 0.7 0.1 85.7% 
Breathlessness 
(Shwas Krichhrita) 
Group-I 0.4 0.2 44.5% 
Group-II 1.2 0.6 53% 
Group-III 1.0 0.4 60% 
 
Criteria Group Mean 
Diff.  
SD+ SE+  ‘t’  
value  
‘p’  
value  
Intergroup  
p-value 
Headache 
(Shiroruja) 
 
Group-I 0.667 0.500 0.167 4.000 0.004 0.307 
Group-II 0.778 0.441 0.147 5.292 <0.001 
Group-III 1.000 0.471 0.149 6.708 <0.001 
Giddiness 
(Bhrama) 
Group-I 0.444 0.527 0.176 2.530 0.035 0.068 
Group-II 0.667 0.500 0.167 3.500 0.004 
Group-III 1.000 0.471 0.149 6.000 <0.001 
Palpitation 
(Hriddravata) 
Group-I 0.333 0.500 0.167 2.000 0.081 0.614 
Group-II 0.444 0.527 0.176 2.530 0.035 
Group-III 0.600 0.699 0.221 2.714 0.024 
Breathlessness 
(Shwas 
Krichhrita) 
Group-I 0.111 0.333 0.111 1.000 0.347 0.065 
Group-II 0.556 0.527 0.176 3.162 0.013 
Group-III 0.600 0.516 0.163 3.674 0.005 
Table 4: Effect of therapy on Hematological Profile 
Variable Group  Mean Score  Percent 
Change  BT AT 
Haemoglobin Group-I 12.66 12.68 0.16% 
Group-II 12.57 12.68 0.95% 
Group-III 11.71 11.76 0.43% 
TLC Group-I 6611.11 6900.00 1.03% 
Group-II 6890.00 6900.00 0.15% 
Group-III 6140.00 6223.00 1.33% 
ESR Group-I 20.00 19.56 2.20% 
Group-II 17.00 16.80 1.18% 
Group-III 14.0 13.8 1.43% 
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Variable Group Mean Diff.  SD+ SE+  ‘t’ value  ‘p’ value  
Haemoglobin Group-I 0.09 1.203 0.380 0.237 0.818 
Group-II 0.01 0.513 0.171 0.064 0.950 
Group-III 0.05 0.576 0.182 0.275 0.790 
TLC Group-I 244.44 418.66 139.55 1.752 0.118 
Group-II 38.33 245.52 81.838 0.543 0.602 
Group-III 83.00 201.11 63.597 1.305 0.224 
ESR Group-I 1.89 3.480 1.160 1.628 0.142 
Group-II 0.89 3.756 1.252 0.710 0.498 
Group-III 0.33 2.582 0.816 1.225 0.252 
Table 5: Effect of therapy on Biochemical Profile 
Variable Group  Mean Score  Percent Change  
BT AT 
FBS Group-I 90.80 94.11 3.65% 
Group-II 92.10 90.67 1.55% 
Group-III 94.40 93.70 0.74% 
B. Urea Group-I 24.60 23.89 2.89% 
Group-II 27.70 27.00 2.52% 
Group-III 30.90 30.20 2.26% 
S. Creatinine Group-I 0.91 0.89 2.31% 
Group-II 0.90 0.88 2.44% 
Group-III 0.87 0.84 3.44% 
SGOT Group-I 34.80 33.22 4.53% 
Group-II 30.80 30.11 0.74% 
Group-III 38.10 37.80 0.78% 
SGPT Group-I 21.40 21.00 1.87% 
Group-II 30.00 29.78 0.74% 
Group-III 33.80 32.90 2.66% 
S. Cholestrol Group-I 166.90 161.00 3.54% 
Group-II 169.90 169.20 0.41% 
Group-III 169.90 167.40 1.47% 
Triglycerides Group-I 185.00 180.00 2.70% 
Group-II 191.90 183.78 4.23% 
Group-III 113.80 112.90 0.79% 
HDL Group-I 55.20 53.89 2.35% 
Group-II 59.40 57.11 3.85% 
Group-III 64.20 66.10 2.96% 
LDL Group-I 89.20 84.44 5.33% 
Group-II 89.20 86.11 3.46% 
Group-III 83.40 81.70 2.04% 
VLDL Group-I 43.50 42.22 2.93% 
Group-II 42.00 41.22 1.85% 
Group-III 26.80 25.90 3.36% 
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Variable Group Mean Diff. SD+ SE+  ‘t’ value  ‘p’ value  
FBS Group-I 2.67 10.075 3.358 0.794 0.450 
Group-II 0.56 4.216 1.405 0.395 0.703 
Group-III 5.30 14.667 4.638 1.143 0.283 
B. Urea Group-I 0.56 1.424 0.475 1.170 0.276 
Group-II 0.44 1.590 0.530 0.839 0.426 
Group-III 0.70 6.684 2.114 0.331 0.748 
S. Creatinine Group-I 0.03 0.180 0.060 0.555 0.594 
Group-II 0.02 0.067 0.022 1.000 0.347 
Group-III 0.03 0.149 0.004 0.635 0.541 
SGOT Group-I 0.33 20.803 6.934 0.048 0.963 
Group-II 0.22 1.202 0.401 0.555 0.594 
Group-III 0.33 12.193 3.856 0.856 0.414 
SGPT Group-I 0.22 0.450 0.494 0.450 0.665 
Group-II 0.22 4.919 1.640 0.136 0.896 
Group-III 0.90 1.912 0.605 1.489 0.171 
S. Cholesterol Group-I 0.22 57.286 19.095 0.012 0.991 
Group-II 0.70 8.301 2.625 0.267 0.796 
Group-III 2.50 8.985 2.841 0.880 0.402 
Triglycerides Group-I 5.00 24.367 8.122 0.862 0.414 
Group-II 20.56 98.434 32.811 0.626 0.548 
Group-III 0.90 29.316 9.271 0.097 0.925 
HDL Group-I 0.22 12.686 4.229 0.052 0.959 
Group-II 3.11 5.798 1.933 1.610 0.330 
Group-III 1.90 11.396 3.604 0.527 0.611 
LDL Group-I 3.33 14.309 4.770 0.699 0.504 
Group-II 1.67 11.057 3.686 0.452 0.663 
Group-III 3.70 11.676 4.008 1.422 0.189 
VLDL Group-I 0.28 4.062 1.354 1.477 0.178 
Group-II 0.78 17.937 5.312 0.775 0.461 
Group-III 1.50 8.631 2.729 0.550 0.596 
DISCUSSION 
In present study maximum patients were 
females. It may be because the prevalence of 
hypertension is more in females after the age of 40. 
This suggests that the oestrogen probably play a 
part in preventing or delaying hypertension[5]. 
Maximum patients had sedentary life style. 
Sedentary life style associated with several 
cardiometabolic factors, including obesity, low 
high-density lipoprotein cholesterol, high 
triglycerides etc. are the main risk factors of blood 
pressure, which in long run can lead to 
development of systemic arterial hypertension[6]. In 
present study patients were found addicted to 
alcohol and smoking. Factors like alcohol 
consumption and smoking are documented 
determinants of hypertension. Addiction of alcohol 
has been reported in 5 to 30% of all hypertensive 
and also causes resistance to antihypertensive 
treatments. Maximum registered patients were 
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taking mixed diet. In different research it was found 
that vegetarians had blood pressure that was 
significantly lower than who took non-vegetarian 
diet. Although the available evidence is limited, 
according to a previous meta-analysis of controlled 
trials, vegetarian dietary patterns significantly 
reduced systolic and diastolic blood pressure. One 
of the common features of a vegetarian diet is 
weight loss, which might, at least partially, explain 
the effect on BP. Other possible factors such as 
sodium, potassium, protein, amino acids, vitamin B-
12, antioxidants, fiber, and the microbiome are 
introduced as possible mechanisms[7]. 
In the present study maximum registered 
patients had Madhyama Vyayama Shakti and Avara 
Vayayam Shakti. Exercise increases blood 
circulation, reduce platelet stickiness, increases 
fibrinolysis, lower blood lipids and reduces obesity. 
Exercise appears to have a positive effect on 
remodelling of the hypertensive heart and 
prevention of LVH[8]. 
 The mean score of systolic blood pressure 
before treatment in Group-I was 148.60mm of Hg 
which decreased to 134.67mm of Hg after 
treatment with 9.374% reduction, which was 
statistically highly significant (p<0.001). In Group-II 
the initial mean score of systolic blood pressure was 
150.10mm of Hg which decreased to 126.89mm of 
Hg after treatment with 15.46% reduction which 
was highly significant (p<0.001). Whereas in Group-
III initial mean score of systolic blood pressure was 
153.00mm of Hg which decreased to 127.200mm of 
Hg after treatment with 16.86% reduction which 
was highly significant (p<0.001). 
 Similarly the initial mean score of diastolic 
blood pressure in Group-I was 89.8mm of Hg, which 
decreased to 82.44mm of Hg after treatment with 
8.195% reduction which was statistically significant 
(p=0.001). In Group-II the initial mean score of 
diastolic blood pressure was 92.4mm of Hg, which 
decreased to 82.0mm of Hg after treatment with 
11.250% reduction which was highly significant 
(p<0.001). In Group- III the initial mean score of 
diastolic blood pressure was 92.00mm of Hg, which 
decreased to 80.80mm of Hg after treatment with 
12.17% reduction which was highly significant 
(p<0.001). The intergroup comparison of effect of 
therapy on systolic blood pressure observed after 
the completion of therapy was statistically 
significant (p= 0.002). The intergroup comparison 
of effect of therapy on diastolic blood pressure 
observed after the completion of therapy was 
statistically insignificant (p =0.187).  
 In Group- I initial mean score of mean 
arterial pressure was 109.7mm of Hg which 
decreased to 99.73mm of Hg after treatment with 
9.088% reduction which was statistically highly 
significant (p<0.001). In Group-II mean score of 
mean arterial pressure was 112.0mm of Hg which 
decreased to 96.93mm of Hg after treatment with 
13.46% reduction which was statistically highly 
significant (p<0.001). 
 In Group III, the initial mean score of mean 
arterial pressure was 112.29mm of Hg which 
decreased to 96.24mm of Hg after treatment with 
14.28% reduction which was statistically highly 
significant (p<0.001). The intergroup comparison of 
effect of therapy on mean arterial blood pressure 
observed after the completion of therapy was 
statistically significant (p =0.013). 
In Group- I mean score of pulse pressure 
was 59.8mm of Hg which decreased to 52 mm of Hg 
after treatment with 13.04% reduction which was 
statistically significant (p=0.005). In Group II mean 
score of mean arterial pressure was 58.9mm of Hg 
which decreased to 44.89mm of Hg after treatment 
with 23.7% reduction which was statistically 
significant (p=0.008). In Group III mean score of 
mean arterial pressure was 61.00mm of Hg which 
decreased to 46.40mm of Hg after treatment with 
23.93% reduction which was statistically highly 
significant (p=<0.001). The intergroup comparison 
of effect of therapy on pulse pressure observed 
after the completion of therapy was statistically 
insignificant (p= 0.071). 
 In Group-I, mean score of pulse pressure 
was 76.40mm of Hg which decreased to 74mm of 
Hg after treatment with 3.141% reduction which 
was statistically insignificant (p=0.315). In Group-
1I, mean score of pulse pressure was 73.20 mm of 
Hg which decreased to 73.11mm of Hg after 
treatment with 0.122% reduction which was 
statistically insignificant (p=0.804). In Group-III, 
mean score of mean arterial pressure was 76.80mm 
of Hg which decreased to 73.00mm of Hg after 
treatment with 4.947% reduction which was 
statistically insignificant (p=0.169). On comparing 
the inter group difference, there was insignificant 
difference in reduction of pulse rate (p=0.672).  
 Out of 30 registered patients of Stage 1 
Hypertension, 83.33% (25) patients had Shiroruja, 
83.33% (25) patients had Bhrama, 56.67% (17) 
patients had Shwasa Kricchta and 53.33% (16) 
patients had Hriddravata. 
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In Group-I the initial mean score of 
Shiroruja in Group-I was 1.6, which decreased to 
1.11 after treatment with 30.64% reduction which 
was statistically significant (p=0.004). In Group-II 
mean score of Shiroruja was 1.4 which decreased to 
0.778 after treatment with 44.24% reduction which 
was statistically highly significant (p=<0.001). In 
Group- III the initial mean score of Shiroruja in this 
group was 1.9 which decreased to 0.90 after 
treatment with 52.63% reduction which was 
statistically highly significant (p=<0.001). The 
intergroup comparison of effect of therapy on 
Shiroruja observed after the completion of therapy 
was statistically insignificant (p =0.307). 
 In Group-I the initial mean score of Bhrama 
in group I was 1.1, which decreased to 0.556 after 
treatment with 40% reduction which was 
statistically significant (p=0.035). In Group II initial 
mean score of Bhrama was 1.2 which decreased to 
0.556 after treatment with 53% reduction which 
was statistically significant (p=0.004). In Group III 
the initial mean score of Bhrama was 1.7 which 
decreased to 0.7 after treatment with 58% 
reduction which was statistically highly significant 
(p=<0.001). The intergroup comparison of effect of 
therapy on Bhrama observed after the completion 
of therapy was statistically insignificant (p =0.068).  
In Group I the initial mean score of 
Hriddrava was 0.500, which decreased to 0.222 
after treatment with 55.6% reduction which was 
statistically insignificant (p=0.081). In Group-II 
mean score of Hriddrava in was 0.700 which 
decreased to 0.222 after treatment with 68.2% 
reduction which was statistically significant 
(p=0.035). In Group-III mean score of Hriddrava 
was 0.700 which decreased to 0.1000 after 
treatment with 85.7% reduction which was 
statistically significant (p=0.024). The intergroup 
comparison of effect of therapy on Hriddrava 
observed after the completion of therapy was 
statistically insignificant (p =0.614).  
 In Group- I the initial mean score of Shwas 
Krichhrita was 0.400, which decreased to 0.222 
after treatment with 44.5% reduction which was 
statistically insignificant (p=0.347). In Group –II, 
mean score of Shwas Krichhrita was 1.200 which 
decreased to 0.556 after treatment with 53% 
reduction which was statistically significant 
(p=0.013). In Group-III, initial mean score of Shwas 
Krichhrita was 1.000 which decreased to 0.400 after 
treatment with 60% reduction which was 
statistically significant (p=0.005). The intergroup 
comparison of effect of therapy on Shwas Krichhrita 
observed after the completion of therapy was 
statistically insignificant (p =0.065).   
Laboratory Profile 
 Hematological profile of the registered 
patients under study revealed that Haemoglobin, 
TLC, DLC and ESR in all three groups were within 
normal limits both before and after therapy.  
 Biochemical profile of the registered 
patients under study revealed that FBS, B. Urea, S. 
Creatinine, SGOT, SGPT, S.Cholesterol, TG, HDL, LDL, 
VLDL in all three groups were within normal limits 
both before and after the therapy.  
 Hypertension is a Tridosha Vyadhi with Vata 
predominance. It has Tridosha Shamaka property. 
This drug alleviates vitiated Vata by virtue of its 
Snigdha Guna, Madhura Rasa and Madura Vipaka 
and Pitta with its Madhura Rasa, Madhura Vipaka 
and Sheeta Veerya and Kapha by its Kashaya Rasa. 
By Tridosh Shamaka effect it helps in reducing the 
blood pressure. 
 Trinpanchmool is Mootra Virechniya drug. 
These drugs perform their action by decreasing the 
Agneyatatva and increasing the Jaliyatatva in the 
urine. They do Pitta- Shaman and Vata- Anuloman. 
In the recent studies all the drugs found to have 
diuretic property. They was found to be effective in 
increasing urinary electrolyte concentration (Na+, 
K+ and Cl-) and increases the urine quantity 
resulting in reduction of intravascular volume 
which may in turn lead to reduction in blood 
pressure. 
CONCLUSION 
On clinical evaluation, the trial drug 
Trinpanchmool Kwath has proved effective and safe 
for patients of essential hypertension. Results 
revealed that therapy given in Group-III i.e., the 
combination of Trinpanchmool Kwath and Tab. 
Chlorthalidone showed best results as compared to 
other groups. Group-II, in which patients were 
managed with Tab Chlorthalidone showed better 
results over Group-I where only Trinpanchmool 
Kwath was given to the patients. However 
statistically highly significant reduction in both 
systolic and diastolic pressure was observed in all 
three groups. No untoward effect of therapy was 
observed in both the groups during the entire trial 
period. 
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